CoChat

Phase 2 study of sodium phenylbutyrate in ALS

Cudkowicz, Merit E., Andres, Patricia L., Macdonald, Sally A., Bedlack, Richard S., Choudry, Rabia, Brown Jr, Robert H., Zhang, Hui, Schoenfeld, David A., Shefner, Jeremy, Matson, Samantha, Matson, Wayne R., Ferrante, Robert J., THE NORTHEAST ALS AND THE NATIONAL · 2009 · Amyotrophic Lateral Sclerosis
Cited by 154

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The objective of the study was to establish the safety and pharmacodynamics of escalating dosages of sodium phenylbutyrate (NaPB) in participants with ALS. Transcription dysregulation may play a role in the pathogenesis of ALS. Sodium phenylbutyrate, a histone deacetylase inhibitor, improves transcription and post-transcriptional pathways, promoting cell survival in a mouse model of motor neuron disease. Forty research participants at eight sites enrolled in an open-label study. Study medication was increased from 9 to 21 g/day. The primary outcome measure was tolerability. Secondary outcome measures included adverse events, blood histone acetylation levels, and NaPB blood levels at each dosage. Twenty-six participants completed the 20-week treatment phase. NaPB was safe and tolerable. No study deaths or clinically relevant laboratory changes occurred with NaPB treatment. Histone acetylation was decreased by approximately 50% in blood buffy-coat specimens at screening and was significantly increased after NaPB administration. Blood levels of NaPB and the primary metabolite, phenylacetate, increased with dosage. While the majority of subjects tolerated higher dosages of NaPB, the lowest dose (9 g/day), was therapeutically efficient in improving histone acetylation levels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/17482960802320487

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 154

Metadata

Authors
Cudkowicz, M. E., Andres, P. L., Macdonald, S. A., Bedlack, R. S., Choudry, R., Brown Jr, R. H., Zhang, H., Schoenfeld, D. A., Shefner, J., Matson, S., Matson, W. R., Ferrante, R. J., & NATIONAL, T. N. A. A. T.
Venue
Amyotrophic Lateral Sclerosis
Published
2009-01
Volume
10
Issue
2
Pages
99-106
ISSN
  • 1471-180X (ISSN-L)
  • 1748-2968
OpenAlex
W2128206335
Cited by
154
References
5
FWCI
5.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 2 study of sodium phenylbutyrate in ALS. https://app.cochat.ai/papers/10.1080/17482960802320487
The paper
Cudkowicz, M. E., Andres, P. L., Macdonald, S. A., Bedlack, R. S., Choudry, R., Brown Jr, R. H., Zhang, H., Schoenfeld, D. A., Shefner, J., Matson, S., Matson, W. R., Ferrante, R. J., & NATIONAL, T. N. A. A. T. (2009). Phase 2 study of sodium phenylbutyrate in ALS. Amyotrophic Lateral Sclerosis. https://doi.org/10.1080/17482960802320487

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.